48 results about "Active domain" patented technology

The invention discloses a method for detecting data collection omission in a traffic collection device and relates to an information security technology in the technical field of information. The method comprises the following steps: step 1 is discovery of omission of active IP data, and step 2 is discovery of omission of active domain name data. According to the invention, a DNS data source is used to supplement original data, and data which has the attribute of a computer room is extracted, and then a simulation request is performed, such that the performance demand for the simulation request is reduced, a more comprehensive simulation request is also provided, and discovered omission is more comprehensive and accurate. When the simulation request is performed, an http (get/post) requestis firstly performed, and then afterwards, data whose simulation request result return values are not within a reasonable scope is subjected to an https (get/post) request. Such a mode, compared to amode of performing http&https simulation requests on all data, can reduce the performance demand for the simulation request, and compared to a mode of only performing the http simulation request, canalso enhance comprehensiveness of the simulation request. According to the invention, the network supervision level can be effectively improved, and data missed by an information security managementsystem is discovered for analysis of omission reasons of the information security management system.

The present invention concerns a process by which a misfold in an Fc fusion molecule can be prevented or corrected. In one embodiment, the process comprises (a) preparing a pharmacologically active compound comprising an Fc domain; (b) treating the fusion molecule with a copper (II) halide; and (c) isolating the treated fusion molecule. The pharmacologically active compound can be an antibody or a fusion molecule comprising a pharmacologically active domain and an Fc domain. The preferred copper (II) halide is CuCl₂. The preferred concentration thereof is at least about 10 mM for fusion molecules prepared in E. coli; at least about 30 mM for fusion molecules prepared in CHO cells. The process can be employed with any number of pharmacologically active domains. Preferred pharmacologically active domains include OPG proteins, leptin proteins, soluble portions of TNF receptors (e.g., wherein the fusion molecule is etanercept), IL-1ra proteins, and TPO-mimetic peptides. The Fc domain preferably has a human sequence, with an Fc sequence derived from IgG1 most preferred. An exemplary Fc sequence is shown in FIG. 5 hereinafter.

The present invention relates to a method of identifying compounds useful in inhibiting protein kinase-like endoplasmic reticulum protein kinase (PERK). The method comprises providing a first model comprising PERK active domains, where the said active domains are selected from the group consisting of the peptide spanning from amino acid residue Asp144 to amino acid residue Ser191 of SEQ ID NO: 1 and a peptide comprising the amino acid residue at position 7 of SEQ ID NO: 1, providing one or more candidate compounds, evaluating contact between the candidate compounds and the first model to determine which of the one or more candidate compounds have an ability to bind to and/or fit in the first model, and identifying the compounds which, based on said evaluating, have the ability to bind to and/or fit in the first model as compounds potentially useful for inhibiting PERK. The present invention further relates to compounds that can be used for inhibition of PERK, for example human PERK, and methods related to treatment of PERK-mediated diseases.

The present invention relates to chimeric polypeptides comprising a first portion, which comprises a bacteriocin cell wall-binding domain (CBD) and a second portion, which comprises an enzymatic active domain (EAD) selected from the lytic domain of a bacteriophage lysin, a bacteriocin and a bacterial autolysin. Provided are such chimeric polypeptides and variants and fragments thereof, nucleic acids encoding the same, vectors carrying such nucleic acids and host cells transformed or transfected with such vectors. The chimeric polypeptides of the present invention are useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, chimeric polypeptides of the present invention have been shown to effectively kill various bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), as well as other human pathogens. Thus, provided are compositions comprising chimeric polypeptides according to the present invention, variants or fragments thereof, and the use of such compositions in prophylaxis or therapy of bacterial diseases, bacterial infections or bacterial colonisations.

The embodiment of the invention discloses a method, a device and a system for storing data. The method for storing data comprises the following steps: data reading and wiring operation is performed on nodes in an active domain and a dormant domain which are divided in advance during the non-idle time period of a system, and data reading and wiring operation is performed on nodes in the active domain which is divided in advance during the idle time period of the system. The nodes in the dormant domain are in a standard working state during the non-idle time period of the system and in a low-power consumption state during the idle time of the system. During the idle time period of the system, data reading and wiring operation is only performed on the nodes in the active domain, while the nodes in the dormant domain are in the low-power consumption state. The invention can effectively reduce the power consumption of the whole system on condition that the data access requirement is met.

A deoxyribonse of anti-respiratory tract syncytium virus and its medicinal use are disclosed. The deoxyribonse has purine in RSV RNA nucleotide sequence; pyramine site cracks RNA catalytic active domain specially, the No.1 combined domain adjacent to catalytic domain 5' end is supplemented combined with base sequence specificity at one side of RSV RNA incision site; the No.2 combined domain adjacent to catalytic domain 3' end is supplemented combined with base sequence specificity at one side of RSV RNA incision site. It contains 0.01mg-20mg/50 mu l anti-respiratory tract syncytium virus deoxyribonse solution. It is non-toxic, has better medicine sensitivity and can inhibit respiratory tract syncytium virus duplication specially.

The invention generally relates to polyunsaturated fatty acid (PUFA) polyketide synthase (PKS) systems isolated from or derived from non-bacterial organisms, to homologues thereof, to isolated nucleic acid molecules and recombinant nucleic acid molecules encoding biologically active domains of such a PUFA PKS system, to methods of making and using such system for the production of bioactive molecules of interest, and to novel methods for identifying new bacterial and non-bacterial microorganisms having such a PUFA PKS system.

A substrate having a pattern of magnetic properties may be formed by forming a magnetically inactive layer on the substrate, forming a magnetic precursor on the magnetically inactive layer, and forming magnetically active domains separated by magnetically inactive domains in the magnetic precursor by applying thermal energy to the magnetic precursor. The thermal energy may be applied using a laser, which may be pulsed. Forming the magnetically active domains may include crystallizing portions of the magnetic precursor.

The invention discloses a method and device for validity diagnosing of active domain names in an IDC computer room. The method for validity diagnosing of the active domain names in the IDC computer room comprises the following steps: judging whether an obtained real server IP belongs to a local server IP or not by comparing the obtained real server IP information with all server IP information of the local IDC computer room; judging whether an obtained displaying server IP belongs to the real server IP or not by comparing the obtained real server IP information with the displaying server IP information; and determining an active domain name to be tested as a valid active domain name if the obtained real server IP belongs to the local server IP and the displaying server IP belongs to the real server IP. By means of the method provided by the invention, the validity of the active domain names is judged, and invalid domain names, domain names which do not correspond to the displaying server IP address but can be accessed and domain names which do not belong to the local IDC computer room can be effectively filtered out, therefore, the authenticity and accuracy of the active domain names can be furthest insured.

The invention relates to the field of microbiology, specifically to a combination of a source of a first enzymatic active domain and a source of a second enzymatic active domain and to a composition comprising said combination. The invention further relates to a composition comprising said combination for use as a medicament, to the use of said composition as an antimicrobial agent and to a method for controlling microbial contamination in a food- or feed product, on and/or in food- or feed processing equipment, on and/or in food- or feed containers.

The present invention relates to novel methods of generating and screening for chimeric polypeptides, which can be used in the treatment and prophylaxis of pathogenic bacterial contamination, colonisation and infection. The novel methods are based on random recombination of protein domains, and the chimeric polypeptides obtainable by the methods according to the invention are characterized in that they comprise at least one enzymatic active domain (EAD) and at least one cell binding domain (CBD). The present invention also relates to a library of chimeric polypeptides obtainable by the methods of the present invention.

A novel gene defining a novel enzyme in the UDP-D-galactose: b-N-acetyl-glucosamine β-1,4-galactosyltransferase family, termed β4Gal-T2, with unique enzymatic properties is disclosed. The enzymatic activity of β4Gal-T2 is shown to be distinct from that of previously identified enzymes of this gene family. The invention discloses isolated DNA molecules and DNA constructs encoding β4Gal-T2 and derivatives thereof by way of amino acid deletion, substitution or insertion exhibiting β4Gal-T2 activity, as well as cloning and expression vectors including such DNA, cells transfected with the vectors, and recombinant methods for providing β4Gal-T2. The enzyme β4Gal-T2 and β4Gal-T2-active derivatives thereof are disclosed, in particular soluble derivatives comprising the catalytically active domain of β4Gal-T2. Further, the invention discloses methods of obtaining β-1,4-galactosyl glycosylated saccharides, glycopeptides or glycoproteins by use of an enzymically active β4Gal-T2 protein or fusion protein thereof or by using cells stably transfected with a vector including DNA encoding an enzymatically active β4Gal-T2 protein as an expression system for recombinant production of such glycopeptides or glycoproteins. Also a method for the identification of DNA sequence variations in the β4Gal-T2 gene by isolating DNA from a patient, amplifying β4Gal-T2-coding exons by PCR, and detecting the presence of DNA sequence variation, are disclosed.

Murine retroviruses are the most important transfer systems for human gene therapy. However, their application is currently limited. One of the major restrictions both for an application in vivo resides in the problem that this virus type is sensitive to inactivation by human complement factors. Our invention overcomes this limitation. We have modified murine recombinant retroviruses in a way that they are resistant to human complement factors. This was achieved by genetic modification of the retroviral surface protein env which is responsible for receptor interaction: the receptor interacting domain of env was fused to catalytically active domains of human complement inactivation factors. These modified env were expressed in complement-sensitive cells and specifically integrated into virus particles. By this strategy cells and viruses are generated that are fully resistant to complement attack. Thus, this strategy provides a tool for establishment of complement resistant cells and generation of viruses for in vivo gene therapy.